Discontinued in 2013: oncology drugs

@article{Williams2015DiscontinuedI2,
  title={Discontinued in 2013: oncology drugs},
  author={Robert Williams},
  journal={Expert Opinion on Investigational Drugs},
  year={2015},
  volume={24},
  pages={110 - 95}
}
  • Robert Williams
  • Published 2 January 2015
  • Biology
  • Expert Opinion on Investigational Drugs
Introduction: Attrition in clinical development is widely recognised as a key factor negatively impacting overall R&D efficiency. Gaining an understanding of the reasons for candidate failure may lead to improvements in success rates and return on R&D investment. Areas covered: This report provides an analysis of reasons for discontinuation of development of 40 drugs dropped from the global oncology pipeline in 2013 – the largest number of terminations reported since this annual analysis began… 
View on Taylor & Francis
ncbi.nlm.nih.gov
53 Citations
Highly Influential Citations
1
Background Citations
21
Methods Citations
2
Results Citations
2

53 Citations

Citation Type

Citation Type

The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system
TLDR
This study is focused on the high attrition rate in discovery and development of oncology and central nervous system medicines, because the failure rate of these medicines is higher than others.
Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review.
Precision medicine needs randomized clinical trials
TLDR
The view that the expected benefits from new drugs are generally sufficient to forgo a randomized trial with patients assigned to a control arm is challenged and an increased use of randomization is proposed to facilitate a seamless transition between phases of drug and/or biomarker development.
Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials
TLDR
The latest advancements in the development of anti-RON ADCs for targeted cancer therapy are discussed including drug conjugation profile, pharmacokinetic properties, cytotoxic effect in vitro, efficacy in tumor models, and toxicological activities in primates.
The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery
TLDR
A mini-review on the reemergence of PDD in drug development is provided, highlighting the potential of porcine cancer models for improving pre-clinical drug discovery and testing and the precision medicine based genetically defined swinecancer models developed to date and their potential as biomedical models.
A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model
TLDR
In this study, iniparib was well tolerated as a single agent and in combination with carboplatin over a range of doses and clinically relevant concentrations of the parent drug and selected metabolites were not detectable in canine tumor tissues at any studied dose, thus eliminating expectations for clinical responses in dogs or humans.
Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer.
Medulloblastoma drugs in development: Current leads, trials and drawbacks.
Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review
TLDR
Early multidisciplinary approaches using extensive radical surgery, in combination with adjuvant chemo-radiation using either docetaxel/pacitaxel or cisplatin, provided the best chance of disease control and targeted multi-tyrosine kinases inhibitors helped to limit disease progression.
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin
TLDR
A multiscale, mechanism-based model has been developed for inotuzumab ozogamicin, which can integrate preclinical biomeasures and PK/PD data to predict clinical response and indicated that tumor growth is a highly sensitive parameter and predictive of successful outcome.
...
...

References

SHOWING 1-10 OF 20 REFERENCES
Discontinued drugs in 2012: oncology drugs
TLDR
It is noteworthy that while there is clearly still room for improvement in the efficiency of drug development, increased collaboration among academics, industry, regulators, government and not-for-profit organisations appears to be contributing to increased numbers of new drug approvals.
Drug development and clinical trials—the path to an approved cancer drug
TLDR
This Review highlights new approaches in preclinical and clinical drug development that will help accelerate approval of drugs, and aim to provide more-effective treatments alongside companion diagnostic tests to ensure the right treatment is given to the right patient.
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
TLDR
The development of iniparib is scrutinized from preclinical studies to registration trials, and the pitfalls in the development of anticancer drugs are identified to prevent future late-stage trial failures.
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
TLDR
A comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010 allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which are described as the five 'R's'.
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.
How to improve R&D productivity: the pharmaceutical industry's grand challenge
TLDR
A detailed analysis based on comprehensive, recent, industry-wide data is presented to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity and propose specific strategies that could have the most substantial impact in improving R &D productivity.
Phase I trials of targeted anticancer drugs: a need to refocus
As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial…
Incorporating biomarkers into clinical trial designs: points to consider
In an environment where the regulatory and reimbursement authorities continue to raise the bar for new oncology therapies, how are sponsors adapting clinical trial designs?
Does Size Matter?: Clinical Applications of Scaling Cardiac Size and Function for Body Size
TLDR
The critical role of body size measurements in cardiovascular medicine is described and the experimental evidence, theoretical basis, and clinical application of scaling of various functional parameters are presented.
...
...